We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Hologic Acquires Biolucent

By HospiMedica staff writers
Posted on 01 Oct 2007
Hologic, Inc. (Bedford, MA, USA), a leading provider of diagnostic imaging and state-of-the-art digital imaging systems directed towards women's health, has completed the acquisition of BioLucent, Inc. (Aliso Viejo, CA, USA), the developer and marketer of the MammoPad breast cushion.

"This acquisition reflects our continued strategy and efforts to offer a comprehensive portfolio of products to serve in the breast cancer detection market, ” said Jack Cumming, chairman and chief executive officer. "The BioLucent MammoPad was designed to benefit women undergoing mammograms by providing more comfort, we believe, better tissue acquisition, and ultimately improved outcomes. It is our hope, with proper training and support the MammoPad can become a standard of care in mammography. We look forward to the opportunities that will develop from this combination as we continue to build value for our shareholders.”

BioLucent's MammoPad decreases the discomfort associated with mammography. BioLucent's primary research and development efforts are directed at its brachytherapy business, which is focused on breast cancer therapy. Prior to the acquisition, BioLucent completed the spin-off of its brachytherapy technology and business to the holders of BioLucent's outstanding shares of capital stock. The new company, Cianna Medical, will manufacture and market the SAVI applicator. As a result, Hologic acquired BioLucent's Mammopad business and related assets.

The aggregate purchase price paid by Hologic to the security holders of BioLucent at the closing of the acquisition, exclusive of certain transaction costs and expenses, was approximately US$70 million, of which amount $65 million was paid by Hologic in shares of Hologic's common stock.

"We are pleased we have finalized this agreement with Hologic,” said Steven Gex, president and CEO of Biolucent, Inc. "We believe Hologic's experience and ability to work with partners to drive the adoption of value-added products in the sales channel will serve as the perfect compliment to our MammoPad breast cushion.”

Hologic is a leading developer, manufacturer, and supplier of medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of digital imaging technology for general radiography and mammography applications. Hologic's core business units are focused on osteoporosis assessment, mammography, and breast biopsy, direct-to-digital X-ray for general radiography applications, and mini C-arm imaging for orthopedic applications.


Related Links:
Hologic
Biolucent
Breast Localization System
MAMMOREP LOOP
Post-Processing Imaging System
DynaCAD Prostate
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Biopsy Software
Affirm® Contrast

Channels

Nuclear Medicine

view channel
Image: CXCR4-targeted PET imaging reveals hidden inflammatory activity (Diekmann, J. et al., J Nucl Med (2025). DOI: 10.2967/jnumed.125.270807)

PET Imaging of Inflammation Predicts Recovery and Guides Therapy After Heart Attack

Acute myocardial infarction can trigger lasting heart damage, yet clinicians still lack reliable tools to identify which patients will regain function and which may develop heart failure.... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.